Eurasian Pharma Awards

Olainfarm and have become the winners in the…

Olainfarm and have become the winners in the nomination “Digital Project of the Year” of the contest for the Eurasian Pharma Awards 2023 for the joint project “In the Rhythm of the Heart”.

The project enables cardiologists and patients with atrial fibrillation to remotely monitor the patient’s condition and ECG parameters for those undergoing antiarrhythmic therapy. This allows assessing the effectiveness and safety of pharmaceutical drugs therapy and enabling informed clinical decisions. The project was implemented by Olainfarm using and Doctor applications.

Andrey Moskvich, the General Director at Olainfarm Russia and Eric Brovko, the Founder and CEO at the platform, were invited to receive awards.

Upon receiving the award, Andrey Moskvich highlighted: “This recognition means that we are heading in the right direction. It will motivate us to develop the project further and help more patients. This is the result of cooperative work of Olainfarm together with the cardiology community and our long-term partner, the team”.

Eric Brovko emphasized: “For us, it is truly valuable to receive such an award because recognition motivates us to drive innovations. This partnership could not be successful without two important principles. First and foremost, it is trust that forms the basis of our relationships, and secondly, it is tolerance for mistakes and a culture of innovation that unites.

Eurasian Pharma Awards

Eurasian Pharma Awards 2023: Olainfarm and Meros Pharm are…

In 2023 in the competition for the Eurasian Pharma Awards in the nomination “Partnership of the Year” the award was presented to Olainfarm and Meros Pharm.

The transformation of collaboration between Olainfarm, a leading pharmaceutical company in the Baltics, and Meros Pharm, a leader in pharmaceutical distribution in Uzbekistan, along with increased investments in product promotion and improvements in both international and local logistics, has yielded tangible results that allow to develop ambitious plans for the future. The exclusive agreement has ensured the availability of Olainfarm products in over 4,000 pharmacies and has led to a 65% increase in sales compared to the previous year.

Elena Bushberg, Executive Director of Olainfarm, highlighted: «As a proverb says a tree is held by its roots, and a person is held by their family and heritage. I would add that success in business is held by good partners».


Unleashing success in pharma: An interview with Elena Bushberg,…

In the ever-changing world of the pharmaceutical industry, companies’ leaders face relentless challenges head-on to success. In the interview, we spoke with Elena Bushberg, Executive Director of Olainfarm, one of the leading pharmaceutical companies in the Eurasia region, about her views on the current situation in the Eurasia region and the future of the industry.
In the interview with Elena Bushberg, we discussed the following questions:

– What are the priorities for your company in Eurasia?
– What trends having the most impact on pharmaceutical markets in the countries of Eurasia do you highlight for your company?
– What planned regulatory changes may affect the development of the pharmaceutical markets in Eurasia?

What are the priorities for your company in the Eurasia region?

Olainfarm is driven by a profound commitment to deliver high quality therapies in the fields of neurology, cardiology, urology, and other therapeutic areas. Our ultimate goal is to enhance the health and improve the quality of life for our patients.

In our pursuit of supporting healthcare professionals, pharmacists, and patients, we are continuously expanding our product portfolio. As the leading pharmaceutical company in the Baltics, we strive to make significant investments in research and development, modernize our facilities, increase our production capacity, and embrace digitalisation processes. These efforts enable us to deliver the essential treatments and therapies needed for the well-being and improved health outcomes of our patients. By staying at the forefront of innovation and technology, we are able to meet the evolving needs of the healthcare industry and make a positive impact on the lives of individuals across the region.

As a socially responsible enterprise, Olainfarm goes beyond its core mission by actively engaging in education initiatives. We are dedicated to making a positive impact in the communities we serve, particularly in Central Asia. Through our support of local initiatives and social projects like “Cosmic Calmness” in Uzbekistan, we strive to change the culture of health awareness and empower individuals to improve their quality of life and life expectancy.

What trends having the most impact on pharmaceutical markets in the countries of the Eurasian region do you highlight for your company?

The Eurasian region is experiencing rapid economic growth and technological advancements. We are witnessing a significant transformation in diagnostics and treatment practices, with a growing number of individuals becoming more conscious of their health. That is a positive trend as it ensures that people can live healthier and longer lives improving their quality and wellbeing. As a key player in the healthcare industry, we are actively contributing to these changes in our respective fields.

In Uzbekistan, we have observed a strong emphasis on population health, with the government and ministries prioritizing access to medicines and healthcare services for the people. These emerging trends have a profound impact on the development of the pharmaceutical market and play a crucial role in shaping our investment decisions related to these countries.

We embrace the opportunities presented by this dynamic region, recognizing the potential for collaboration and innovation. By aligning our strategies with the evolving healthcare landscape, we aim to enhance patient outcomes and contribute to the overall well-being of communities. Our dedication to delivering high-quality therapies and our commitment to sustainable growth are at the forefront of our decision-making process.

What planned regulatory changes may affect the development of the pharmaceutical markets in the Eurasian region?

We closely monitor changes in pricing regulations in all countries we operate, as overregulated markets usually experience stagnation, which lack positive dynamics.

Serialization is also one of our key areas of focus. In fact, Olainfarm was the first European company to successfully transition to serialized product shipments to Uzbekistan. We are confident that we will be well-prepared to ensure timely delivery of serialized products to Kazakhstan and Kyrgyzstan as well.

Furthermore, we pay close attention to developments within the Eurasian Economic Union (EAEU), as regulatory changes within this economic community have a significant impact on the pharmaceutical markets of this region.